KCT0005596尚未招募未知
The efficacy of subcutaneous implantable cardioverter defibrillator for primary prevention of sudden cardiac death in patients with chronic kidney disease.
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 77
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •? Adult patients aged 19 or older
- •? Chronic kidney disease 3-5 stage patients
- •? Patients with left ventricular congestion rate of 35% or less
- •?a patient who has now been inserted with a subcutaneous defibrillator for primary prevention of sudden death, as recommended by medical guideline
排除标准
- •? Those who are vulnerable to clinical research (as defined by KGCP)
- •? Ineligible for subcutaneous defibrillator screening
- •?Patients resuscitated after experiencing cardiac arrest
- •? Patients with a history of ventricular tachycardia
- •? Patients with artificial cardiac pacemakers and parenteral defibrillators
- •? Patients with a life expectancy of less than one year
- •? Patients scheduled for kidney transplantation
- •(viii) Patients who refuse to participate in clinical research
研究者
相似试验
撤回
不适用
Subcutaneous implantable cardioverter-defibrillator screening ECG during exercise in patients vulnerable for T-wave oversensingheart rhythm disturbances1000752110007510NL-OMON38930Academisch Medisch Centrum100
已完成
不适用
Evaluation of the effect of Carrogated drain in reducing SSICondition 1: Acute abdomen. Condition 2: Acut peritonitis. Condition 3: Biliary peritonitis. Condition 4: Fecal peritonitis.Acute abdomenR10.0PeritonitisIRCT20201022049115N1Tehran University of Medical Sciences158
招募中
2 期
The efficacy and safety of subcutaneous injection of bortezomib combined with doxorubicin and dexamethasone for untreated multiple myeloma patients.multiple myelomaJPRN-UMIN000007803ational Hospital Organization Disaster Medical Center35
进行中（未招募）
1 期
/AEUCTR2018-003427-11-ESProbelte Pharma S.L.U.350
进行中（未招募）
1 期
Safety and efficacy of subcutaneous (SC) administration of Clinimix N9G15E in elderly patients at risk for malnutrition, at a dose of 1 liter infused over 12 hours for 7 to 10 consecutive days. A prospective, multicentre, randomized, open-label, non-inferiority, controlled phase III B trial carried out in parallel groups: subcutaneous versus peripheral intravenous administration.EUCTR2007-006153-31-FRBaxter R and D Europe SCR120